组蛋白去乙酰化酶抑制剂联合紫杉醇抑制宫颈癌细胞增殖的体外实验

doi:10.3969/j.issn.1004-616x.2017.05.003

Abstract

Abstract: OBJECTIVE: To investigate the inhibitory effect of paclitaxel and SAHA on human cervical cancer cells. METHODS: Human cervical cancer (HeLa) cells were treated with paclitaxel (10 nmol/L),SAHA (10 μmol/L),or paclitaxel (10 nmol/L) + SAHA (10 μmol/L) for 24 hours or 48 hours. The inhibitory rates of HeLa cells were determined by MTT assay. p27 mRNA levels were determined by RT-PCR assay,protein levels of Ac-H4 were identified by Western blot and IC₅₀ of paclitaxel was calculated by SPSS 16.0. RESULTS: Results from the MTT assay show that the inhibition rates from exposure to the combination of paclitaxel and SAHA were significantly higher than those from the single treatment groups (P < 0.01). Similarly,RT-PCR assay show that the p27 mRNA levels from the combined treatments were significantly higher than from single treatments (P < 0.01). From combined treatments,the inhibitory rates were 54.27%±4.02% with 24 h treatment and 77.02%±3.86% with 48 h treatment,the mRNA level was 10.601±0.673,the protein level of Ac-H4 was 1.282±0.033,and IC₅₀ was reduced significantly. CONCLUSION: SAHA in combination with paclitaxel significantly inhibited HeLa cell proliferation by enhancing the level of histone acetylation and inducing the expression of tumor suppressor genes in vitro.

Key words: SAHA, paclitaxel, cervical cancers, HeLa cell, cell proliferation

CLC Number:

R730.1

LIU Hao, ZHAO Yingying, JIN Ping, XU Gaixia, GUO Yuran, ZHANG Ke, WANG Xiaomei, ZHANG Lei. Histone deacetylase inhibitor restrained proliferation of human cervical cancer cells[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(5): 335-339.

References

[1] FENG D,CAO Z,LI C,et al. Combination of valproic acid and ATRA restores RAR beta2 expression and induces differentiation in cervical cancer through the P13K/Akt pathway[J]. Curr Mol Med,2012,12(3):342-354.
[2] CARAFA V,MICELI M,ALTUCCI L,et al. Histone deacetylase inhibitors:a patent review (2009-2011)[J]. Expert Opin Ther Pat,2013,23(1):1-17.
[3] XU W S,PARMIGIANI R B,MARKS P A. Histone deacetylase inhibitors:molecular mechanisms of action[J]. Oncogene,2007,26(37):5541-5552.
[4] RAJAK H,SINGH A,RAGHWANSHI K,et al. A structural insight into hydroxamic acid based histone deacetylase inhibitors for the presence of anticancer activity[J]. Curr Med Chem,2014,21(23):2642-2664.
[5] TANG J,YAN H,ZHUANG S. Histone deacetylases as targets for treatment of multiple diseases[J]. Clin Sci,2013,124(11):651-662.
[6] KELLY W K,O'CONNOR O A,MARKS P A. Histone deacetylase inhibitors:from target to clinical trials[J]. Expert Opin Investig Drugs,2002,11(12):1695-1713.
[7] MARKS P A. Discovery and development of SAHA as an anticancer agent[J]. Oncogene,2007,26(9):1351-1356.
[8] HAGELKRUYS A,SAWICKA A,RENNMAYR M,et al. The biology of HDAC in cancer:the nuclear and epigenetic components[J]. Handb Exp Pharmacol,2011,206:13-37.
[9] WASABURO K,SAKATA S M. A randomized phase Ⅲ trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial)[J]. Jpn J Clin Oncol,2015,45(3):303-306.
[10] YASUTSUNA S,HIROFUMI Y. Phase Ⅱ trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer[J]. Cancer Sci,2014,105(7):812-817.
[11] HWANG J J,KIM Y S,KIM M J,et al. Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells[J]. J Urol,2010,184(6):2557-2564.
[12] JOHN M,FITZPATRICK A,RONALD-DE W T,et al. Taxane mechanisms of action:potential implications for treatment sequencing in metastatic castration- resistant prostate cancer[J]. Euro A Urolo,2014,65(6):1198-1204.
[13] FERLAY J,SOERJOMATARAM I,ERVIK M,et al. Globocan 2012:estimated cancer incidence,mortality and prevalence worldwide in 2012[EB/OL]. http://globocan.iarc.fr.
[14] YU L L,CHEN W. Technology progress of cervical cancer screening[J]. Chin J Obstet Gynecol,2015,50(4):312-315.
[15] CHEN WANQING,ZHENG RONGSHOU,BAADE P D,et al. Cancer statistice in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[16] CHAVEZ-BLANCO A,SEGURA-PACHECO B,PEREZ-CARDENAS E,et al. Historic acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer.A phase I study[J]. Mol Cancer,2005,4(1):22.
[17] TAN S,DE VRIES E G,VAN DER ZEE A G,et al. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer[J]. Curr Cancer Drug Targets,2012,12(2):170-184.
[18] MORA-GARCIA MDE L,DUENAS-GONZALEZ A,HEMANDEZ-MONTES J,et al. Up-regulation of HLA class-I antigen expression and antigen——specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid[J]. J Ttransl Med,2006,4:55.
[19] MA T,GALIMBERTI F,ERKMEN C P,et al. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer[J]. Mol Cancer Ther,2013,12(8):1545-1555.

Histone deacetylase inhibitor restrained proliferation of human cervical cancer cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[2]	HUANG Xiaohua, NIU Yongdong, SHI Ganggang. Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 302-306.
[3]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[4]	ZHANG Na, FAN Zhilu, YANG Liyan, CHANG Chen, CAI Yan, HAO Jiajie, WANG Mingrong. Clinical significance of decreased SERPINB5 expression in esophageal squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 101-109.
[5]	DU Lu, JIANG Xiaoyan, DING Kuke. Stable knockdown of NF-YB gene in the HeLa cell line [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 409-413.
[6]	LAN Li, CHEN Haili, XU Lei. Mechanism of RBMS3-S3 on the proliferation, apoptosis and invasion of cervical cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 438-443.
[7]	CAO Yu, ZHANG Qiaoye, HUA Rui, MA Xiaoling, WANG Xu, NI Juan. Effects of resveratrol on proliferation and genomic instability of human colon cells NCM460 and SW620 [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(4): 283-288.
[8]	LIU Mengqi, ZHANG Wenwen, CHEN Xiaowei, SHEN Xiaobing. Inhibitory effects of PD98059 on the MAPK/ERK signaling pathway in gastric cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(1): 15-21.
[9]	LI Ge, WANG Yaofei, GAN Na, HE Qi, WANG Guan, HAN Zhanfeng, HAI Chunxu, LIN Zhaoxing. Preliminary study on the role of MnSOD in liver regeneration [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(1): 58-63,78.
[10]	WEN Hairuo, GUO Yajuan, HUANG Zhiying, WANG Xue, DAN Mo. Induction of cytotoxicity and DNA damage by iron oxide nanoparticles with different surface modifications in A549 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(6): 413-421.
[11]	XING Long, LI Yang, MA Xiaolong, MOHAMMED H, HUANG Ying, XIE Fuqiang, FENG Zhenghu. Effects of ethaselen, a novel organoselenium compound, on proliferation and migration of human tongue squamous carcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(4): 279-285.
[12]	WU Yilan, WANG Han. Inhibition of proliferation by resveratrol in paclitaxel-resistant lung adenocarcinoma cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(3): 200-203,208.
[13]	PENG Hui, MA Shumei, HONG Weiwei, SUI Jing, ZHANG Yanqiu, LIANG Geyu. Regulatory mechanism of miR-202 on proliferation of A549 lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(6): 454-459.
[14]	SONG Shufang, CHANG Haiping, YANG Cairong, ZHAO Rongwei, ZHANG Long, REN Jie, ZHENG Jian. Effect and mechanism of lentivirus-mediated silencing of TPX2 gene expression on proliferation, migration and cell cycle of HeLa cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(5): 329-334,339.
[15]	CHEN Ting, ZHENG Zhijia, XU Gaixia, TIAN Jinglin, LIN Suxia, HUANG Jiacheng, LI Jiefeng, HUANG Qijun, WANG Xiaomei, LIN Guimiao. Effect of CdSe/ZnS quantum dots on HepG2 cell viability and apoptosis-related proteins [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2017, 29(1): 18-22.